Holen Sie sich die Stockscreener-App
62.58
4.39%
2.63
Handel nachbörslich:
62.58
Schlusskurs vom Vortag:
$59.95
Offen:
$60
24-Stunden-Volumen:
321.45K
Relative Volume:
1.00
Marktkapitalisierung:
$2.35B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-13.78
EPS:
-4.54
Netto-Cashflow:
$-146.15M
1W Leistung:
+4.06%
1M Leistung:
+2.76%
6M Leistung:
+3.32%
1J Leistung:
+95.93%
1-Tages-Spanne:
$59.47
$62.93
1-Wochen-Bereich:
$57.53
$62.93
52-Wochen-Spanne:
$27.31
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group - MarketBeat
(KROS) Proactive Strategies - Stock Traders Daily
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewswire
Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Emerald Advisers LLC Acquires Shares of 155,545 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $89.11 - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Analysts Offer Predictions for KROS FY2024 Earnings - Defense World
Assenagon Asset Management S.A. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Cantor Fitzgerald Weighs in on KROS FY2024 Earnings - Defense World
Brokers Set Expectations for KROS FY2024 Earnings - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
(KROS) Trading Signals - Stock Traders Daily
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating - Investing.com India
Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Now Covered by Scotiabank - MarketBeat
Keros Therapeutics appoints new Chief Medical Officer - Investing.com
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire
Keros Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com UK
Keros Therapeutics, Inc. Appoints Yung H. Chyung as Chief Medical Officer, Effective as of November 1, 2024 - Marketscreener.com
Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Declines By 13.7% - MarketBeat
Objective long/short (KROS) Report - Stock Traders Daily
Renaissance Technologies LLC Invests $654,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Renaissance Technologies LLC Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Marshall Wace LLP Has $1.02 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Dimensional Fund Advisors LP Sells 3,691 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
19,832 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Squarepoint Ops LLC - Defense World
Squarepoint Ops LLC Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Point72 Asia Singapore Pte. Ltd. Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $90.63 Consensus PT from Analysts - MarketBeat
Understanding the Risks of Investing in Keros Therapeutics Inc (KROS) - Knox Daily
Keros Therapeutics completes enrollment for TROPOS trial - Investing.com India
Leerink Partners sees favorable conditions for Keros Therapeutics shares amid competitive landscape with Winrevair - Investing.com Canada
Nantahala Capital Management LLC Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Nantahala Capital Management LLC Acquires 84,810 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Point72 Asset Management L.P. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics completes enrollment for TROPOS trial By Investing.com - Investing.com South Africa
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Wells Fargo Initiates Coverage of Keros Therapeutics (KROS) with Overweight Recommendation - MSN
Point72 Asia Singapore Pte. Ltd. Purchases New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Blue Owl Capital Holdings LP Sells 15,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Fred Alger Management LLC Has $2.24 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Iron Deficiency Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Shield Therapeutics, Zeria Pharma, Keros Therapeutics - The Globe and Mail
Darwin Global Management Ltd. Boosts Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
17,540 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by Point72 DIFC Ltd - MarketBeat
Keros Therapeutics Inc [KROS] Insider GORDON CARL L sells 250,000 Shares for $250,000 - Knox Daily
Keros Therapeutics Inc (KROS)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World
Keros Therapeutics (NASDAQ:KROS) Receives New Coverage from Analysts at Guggenheim - Defense World
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Keros Therapeutics Inc-Aktie (KROS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):